BERN, Switzerland and BOSTON, Nov. 29, 2023 (GLOBE NEWSWIRE) -- RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI), announces that they are now joining the Ryan Initiative for Macular Research (RIMR) Age-related Macular Degeneration (AMD) Imaging Consortium, a non-profit group of physicians, researchers and industry partners working together to define optimal biomarkers and endpoints in AMD.
RIMR members from around the world will now be able to connect through RetinAI’s cloud-based platform, RetinAI Discovery®, to facilitate a frictionless collaboration and derive insights on global AMD datasets, helping to advance research in this disease that is a leading cause of blindness in older individuals.
AMD is a significant global health concern, affecting about 170 million individuals and ranking as the third leading cause of vision loss worldwide. The United States alone sees a prevalence of AMD similar to that of all invasive cancers combined, contributing to substantial healthcare costs. The disease burden varies by region, as illustrated by studies showing differences in AMD prevalence between Western countries and China, and among ethnic groups globally.
As a member of the RIMR consortium, RetinAI will leverage its innovative digital health technologies as a technology backbone to support RIMR’s international network of leading experts in AMD to aggregate and analyze, at-scale, research and real-world clinical and imaging data. The result will be the generation of a highly diverse database and analysis using AI to help address leading research questions of AMD, such as differences among ethnic groups.
“By being a member of RIMR, we are setting the foundation to connect leading AMD experts from around the world to help advance their important biomarker-led research,” states Dr. Carlos Ciller, CEO of RetinAI. “We are thrilled to be a part of the consortium and help to facilitate cutting-edge research with a shared goal of improving patient care,” he added.
“We’re excited about working with RetinAI as a member of the consortium,” said Dr. SriniVas Sadda, Executive Committee Chair for RIMR, Director of the AI Laboratory at Doheny Eye Institute, and Professor David Geffen, School of Medicine at UCLA. “RetinAI’s focus on digital health technologies and connectivity in Ophthalmology will enable us to build a highly diverse database in AMD, providing the enriched insights to advance our understanding of AMD to drive our goal for finding a cure in AMD.”